It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Adults 18 years or older undergoing ASCT for a hematologic malignancy
Patients providing written informed consent prior to starting transplantation
A previous WHO grade 2, 3 or 4 bleeding event within the past year
A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis
A current provoked thrombotic event (e.g. catheter-related thrombosis) within last month and/or still requiring anticoagulant treatment.
A requirement for therapeutic anticoagulant or anti-platelet drugs during ASCT
Ottawa Hospital Research Institute
Lead sponsor
Alberta Cancer Foundation
Collaborator